Clinical Trial Search

Primary: Change From Baseline in Adenoid/Choana (A/C) Index Grade — 0.3; 0.2; 0.4; 0.3 Score on a Scale

Primary: Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period — 23; 20; 21 participants

Primary: Overall Survival — 399; 324 Days

Primary: Number of Participants With Improvement of at Least 2 Grades in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12 — 129; 82; 100; 59…

Primary: Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score — -4.76; -5.82 scores on a scale

Primary: Target Lesion Failure (TLF) — 2.9; 3.4 percentage of participants — p=0.001

Primary: Microbiological Cure Rate — 94.9; 94.6 percentage of participants cured

Primary: The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone Levels — 93; 57; 12; 45 participants

Primary: Time to Progression (TTP) - Expert Evaluation Committee Assessment — 13.8; 11.1 months

Primary: Change in Sodium Levels — 139.9; 138.1; 138.1; 138.2 mEq/L — p=0.030

Primary: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 — 65; 1 participants — p=<0.0001

Primary: Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.42; 95.62; 96.27; 95.56 Percentage of participants

Primary: Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression — 10; 14; 9; 8 participants

Primary: Number of Participants With Adverse Events and Adverse Drug Reactions — 76; 18 participants

Primary: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) — 660; 813 Days — p=0.0218